Skip to main content
Premium Trial:

Request an Annual Quote

Genome Canada Startup Emerillon Therapeutics to Acquire HemaX Genome in All-Stock Transaction

NEW YORK, Oct. 10 (GenomeWeb News) - Emerillon Therapeutics will acquire HemaX Genome in an all-stock transaction, the Canadian companies said last week.


Under the agreement, Emerillon will acquire all outstanding shares of exchange for Emerillon shares. In addition, GeneChem Technologies, one of HemaX's venture capital investors, will make an equity investment in Emerillon.


Emerillon, which studies genes associated with human complex diseases, was founded in 2003 as a spinoff from Xenon Pharmaceuticals with funding from Genome Canadaand Genome Quebec. "This is the first major involvement of venture capital investment in a Genome Quebec initiated company," said Paul L'Archeveque, president of Genome Quebec, in a statement.


HemaX has been focusing on genes of medical interest on the X chromosome and other genes responsible for diseases with unequal gender distribution.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.